RHYTHM PHARMACEUTICALS, INC. reported first quarter ended March 31, 2026 results: revenue $60.1 million.
“Revenue from global sales of IMCIVREE was $60.1 million for the first quarter of 2026”
RHYTHM PHARMACEUTICALS, INC. — fact timeline
Source-grounded facts extracted from RHYTHM PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
RHYTHM PHARMACEUTICALS, INC.: Amended certificate of incorporation to provide for officer exculpation from fiduciary duty breaches to the fullest extent permitted by Delaware law (effective 2025-06-25).
“On June 24, 2025 Rhythm Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”), which had previously been adopted by the Company’s Board of Directors (the “Board”) subject to stockholder approval at the Annual Meeting.”
RHYTHM PHARMACEUTICALS, INC. reported for the quarter ended March 31, 2024 results: revenue $26.0 million.
“Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update -- First quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 -- -- Phase 3 trial”
RHYTHM PHARMACEUTICALS, INC.: Filing of Certificate of Designations for Convertible Preferred Stock (effective 2024-04-15).
“on April 15, 2024, the Company filed the Certificate of Designations with the Secretary of State of the State of Delaware, effective the same day.”
RHYTHM PHARMACEUTICALS, INC. entered into Investment Agreement with certain affiliates of Perceptive Advisors LLC and certain other investors valued at $150,000,000 (effective 2024-04-01).
“the Company entered into an Investment Agreement (the “Investment Agreement”) with certain affiliates of Perceptive Advisors LLC (“Perceptive”) and certain other investors (each, an “Investor” and collectively, the “Investors”), relating to the issuance and sale of 150,000 shares of a new series of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share, titled the “Series A Convertible Preferred Stock” (the “Convertible Preferred Stock”), for an aggregate purchase price of $150,000,000, or $1,000 per share”
RHYTHM PHARMACEUTICALS, INC. entered into Investment Agreement with certain affiliates of Perceptive Advisors LLC and certain other investors valued at $150,000,000 (effective 2024-04-01).
“On April 1, 2024, Rhythm Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Investment Agreement (the “Investment Agreement”) with certain affiliates of Perceptive Advisors LLC (“Perceptive”) and certain other investors (each, an “Investor” and collectively, the “Investors”), relating to the issuance and sale of 150,000 shares of a new series of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share, titled the “Series A Convertible Preferred Stock” (the “Convertible Preferred Stock”), for an aggregate purchase price of $150,000,000, or $1,000 per share (the “Issuance”).”
RHYTHM PHARMACEUTICALS, INC. reported fourth quarter and full year ended December 31, 2023 results: revenue $24.2 million.
“Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update -- Fourth quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $24.2 million -- -- Enrollment completed in 120-patient, pivotal cohort of Phase 3 setmelanotide trial in hypothalamic obesity; top-line data on track for 1H2025 -- -- Announced Phase 3”
RHYTHM PHARMACEUTICALS, INC. entered into Share Issuance Agreement with LG Chem, Ltd. (effective 2024-01-04).
“The Share Issuance Agreement contains customary representations and warranties by the Company and LGC, and the issuance of the Shares is subject to certain customary closing conditions.”
RHYTHM PHARMACEUTICALS, INC. entered into License Agreement with LG Chem, Ltd. valued at $40 million in cash and issue shares of its common stock, par value of $0.001, with an aggregate val (effective 2024-01-04).
“Under the terms of the License Agreement, the Company will obtain worldwide rights to exploit LGC’s proprietary compound LB54640 and will assume sponsorship of two ongoing LGC Phase 2 studies designed to evaluate safety, tolerability, pharmacokinetics and weight loss efficacy of LB54640.”
RHYTHM PHARMACEUTICALS, INC.: Amended and restated bylaws to adopt universal proxy rules, streamline stockholder nomination procedures, require white proxy card for soliciting stockholders, and delete obsolete provisions (effective 2023-12-14).
“On December 14, 2023, the Board of Directors (the “ Board ”) of Rhythm Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.”
RHYTHM PHARMACEUTICALS, INC. reported the third quarter ended September 30, 2023 results: revenue $22.5 million.
“Third quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $22.5 million”
Christopher German was appointed as Principal Accounting Officer at RHYTHM PHARMACEUTICALS, INC..
“On August 8, 2023, the Board of Directors of the Company designated Christopher German, the Company’s Executive Director, Corporate Controller, as principal accounting officer, effective on the Effective Date.”
William T. Roberts was terminated as Chief Accounting Officer at RHYTHM PHARMACEUTICALS, INC..
“On August 4, 2023, Rhythm Pharmaceuticals, Inc. (the “Company”) notified William T. Roberts, the Company’s Chief Accounting Officer, of the termination of Mr. Roberts’ employment with the Company, to be effective on August 11, 2023”
RHYTHM PHARMACEUTICALS, INC. reported the second quarter ended June 30, 2023 results: revenue $19.2 million.
“Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update -- Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE”
RHYTHM PHARMACEUTICALS, INC. shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers at the 2023-06-21 meeting.
“Item 3 – Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.”
RHYTHM PHARMACEUTICALS, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm at the 2023-06-21 meeting.
“Item 2 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.”
RHYTHM PHARMACEUTICALS, INC. shareholders approved Election of three Class III Directors to serve until the 2026 Annual Meeting of Stockholders at the 2023-06-21 meeting.
“Item 1 - Election of three Class III Directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.”
RHYTHM PHARMACEUTICALS, INC. reported first quarter ended March 31, 2023 results: revenue $11.5 million.
“Net product revenues relating to global sales of IMCIVREE were $11.5 million for the first quarter of 2023, as compared to $1.5 million for the first quarter of 2022.”
RHYTHM PHARMACEUTICALS, INC. reported the year ended December 31, 2022 results: revenue $16.9 million.
“as $8.8 million for the fourth quarter of 2022 and $16.9 million for the year ended Decem”
RHYTHM PHARMACEUTICALS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $8.8 million.
“• Revenue: Product revenue, net relating to global sales of IMCIVREE was $8.8 million for the fourth quarter of 2022”
RHYTHM PHARMACEUTICALS, INC. reported financial results for quarter ended September 30, 2022.
“On November 8, 2022, Rhythm Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.”
RHYTHM PHARMACEUTICALS, INC. terminated RareStone License with RareStone Group Ltd. valued at Termination for cause (effective 2022-10-28).
“On October 28, 2022, Rhythm Pharmaceuticals, Inc. (the “Company”) delivered written notice (the “Notice”) to RareStone Group Ltd. (“RareStone”) that the Company has terminated the exclusive license agreement, dated December 3, 2021, by and between the Company and RareStone (the “RareStone License”) for cause.”
Linda Shapiro Manning was appointed as Chief Medical Officer at RHYTHM PHARMACEUTICALS, INC..
“The Board has appointed Linda Shapiro Manning, M.D., Ph.D., currently Senior Vice President, Clinical of the Company, to succeed Dr. Stewart as Chief Medical Officer as of the Effective Date.”
Murray Stewart resigned as Chief Medical Officer at RHYTHM PHARMACEUTICALS, INC..
“On August 31, 2021, Murray Stewart, D.M., F.R.C.P. notified Rhythm Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Medical Officer, effective as of September 10, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.